CN106589101A - NESFATIN polypeptide and its related substance and use - Google Patents
NESFATIN polypeptide and its related substance and use Download PDFInfo
- Publication number
- CN106589101A CN106589101A CN201611078821.2A CN201611078821A CN106589101A CN 106589101 A CN106589101 A CN 106589101A CN 201611078821 A CN201611078821 A CN 201611078821A CN 106589101 A CN106589101 A CN 106589101A
- Authority
- CN
- China
- Prior art keywords
- nesfatin
- polypeptides
- activity
- body weight
- reactor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a NESFATIN polypeptide and its related substance and use. The NESFATIN polypeptide is a novel anoretic neuropeptide derived from a nucleohistone 2, can be decomposed under action of a prohormone convertase, is a food intake regulation factor and a body weight regulation factor, has activity of food intake inhibition and weight gain inhibition, and contains 420 amino acids. The NESFATIN polypeptide can be obtained by stirring amino acids in a nitrogen blowing way. The NESFATIN polypeptide has obvious effects of food intake inhibition and weight gain inhibition and has a memory function improvement mechanism and an epileptic seizure disturbance mechanism. The NESFATIN polypeptide can be used for treatment on diseases related to feeding disorder and weight regulation, epileptic seizure and enhancement of brain memory functions. The preparation method is simple, the preparation conditions are mild and the preparation cost is low. The NESFATIN polypeptide is worthy of promotion.
Description
Technical field
The present invention relates to technical field of medical chemistry, more particularly to a kind of NESFATIN polypeptides and its related substanceses and use
On the way.
Background technology
Obesity is a kind of chronic metabolic disease caused by many factors, with the volume and cell of body fat cell
Number increases the percentage ratio of cause body fat percentage of liveweight and increases extremely and with the characteristics of the excessive deposition fat in some local, Simple Obesity trouble
Person's total body fat is distributed than more uniform, does not have endocrine regulation phenomenon, and also without dysbolismus disease, often there is obesity in its family
Medical history.Many people suffer from eating be exactly good fortune idea, society now, food species are various, and cuisines of all kinds are lured and often existed,
Almost become a kind of universal amusement along with having a big dinner, become the one of the main reasons for causing obesity, in modern society,
Dietetic life or lack of exercise centered on high fat diet causes the crowd of obesity increasing.At this with thin as beautiful
Epoch, obesity concern the person of outstanding talent of appearance with it is ugly, and pretty with ugly behind in appearance, the bigger problem that obesity is brought is to give people
It is healthy cause serious harm, the daily life for giving people is made troubles, it is often more important that easily cause various concurrent
Disease, accelerates aging and death, obesity be disease tendency, be aging signal.The concurrent cerebral embolism of overweight people and heart failure according to statistics
Sickness rate double than regular severe one, suffer from coronary heart disease two times more than regular severe one, Hypertension incidence compares normal type
Person is more two～six times, and complication with diabetes person about increases 4 times compared with normal person, merges cholelithiasis person compared with normal person Gao Si～six times, more
Life-span for seriously overweight people will substantially shorten.Overweight 10% 45 years old male according to reports, its life-span is than regular severe one
Shorten 4 years, the Japanese statistics of tool show that standard death rate is percentage 100%, and overweight people's mortality rate is 127.9%；And,
Because overweight people's fatty tissue increases, oxygen consumption is increased, and heart amount of work is big, makes myocardial hypertrophy, especially left ventricle burden,
Long easy induction hypertension, lipidosiss cause luminal stenosis, harden in arterial wall, easily occur coronary heart diseases and angina pectoris, in
Wind and sudden death；With metabolism, cryptorrhea caused by obesity, various diseases, abnormal carbohydrate metabolism can be often caused to cause glycosuria
Disease, lipid metabolism can cause hyperlipemia, disorder of nucleic acid metabolism to cause hyperuricemia etc. extremely, and Obese Women is because of ovary machine
Energy obstacle can cause menoxenia, while overweight people's abdominal fat accumulation again limits the respiratory movement of lung, therefore can cause anoxia
And dyspnea, finally result in cardiorespiratory failure；Because the hyperinsulinemia of overweight people closes its endogenous triglyceride
Into hyperfunction, will result in the triglyceride synthesized in liver and accumulate so as to form fatty liver, overweight people compared with normal person, gallbladder
Cholesterol level in juice acid increases, and has exceeded the dissolubility in bile, therefore the easy concurrent a high proportion of cholesterol of overweight people
Calculus, has been reported that the women 50～80% for suffering from cholelithiasis is overweight people.In surgical operation, about by 30% or so high obesity
Person is associated with cholelithiasis, and it is more that cholelithiasis are fallen ill in a case where：Obese women, more than 40 years old, obesity person with it is normal
The sickness rate that the women of body weight compares its cholelithiasis is about high six times.Ingest to keeping body homeostasis, maintaining normal life
Activity is significant, and the regulation process of trophic behavior is sufficiently complex.With fat now more and more universal in the whole world, comprehensively
Understand the treatment that anorexia peptide potentially contributes to fat and energy imbalance relevant disease, in recent years, the body endogenous cause of ill ingested to regulation
The research of son is growing, but plays centrality effect to then which type of factor pair food intake regulation and weight regulation at present
Not yet reach a conclusion, and will not adjust the body intrinsic factor ingested and be applied in the middle of actual treatment.Based on the problems referred to above,
The present invention proposes a kind of NESFATIN polypeptides and its related substanceses and purposes.
The content of the invention
The invention aims to solve shortcoming present in prior art, and a kind of NESFATIN polypeptides for proposing and
Its related substances and purposes.
A kind of NESFATIN polypeptides, the NESFATIN polypeptides are a kind of new anorexia neuropeptides, from core group egg
White 2, the NESFATIN polypeptides are a kind of food intake regulation factors, are also a kind of weight regulation factors；
The preparation method of the NESFATIN polypeptides is：Prepare implosion guard reactor, from the nitrogen introduced below of reactor
Gas, the nitrogen for being passed through reactor is discharged from the top of reactor, aminoacid is added in reactor, using nitrogen by known sequence
The mode of bubbling is stirred to reactant, so as to NESFATIN polypeptides are obtained.
Preferably, the NESFATIN polypeptides have the activity of food rcstriction, the activity for also suppressing with body weight increase.
Preferably, the catabolite NESFATIN-1 of the NESFATIN polypeptides is located at the N-terminal of NUCB2, is by first 82
The peptide chain of aminoacid composition.
Preferably, the NESFATIN polypeptides can decompose under the catalytic action of prohormone convertase.
Preferably, the NESFATIN polypeptides include 420 aminoacid, with SEQ ID NO 3-13,42-58,77-
85th, the aminoacid sequence shown in 112-132.
Preferably, the carrier of the NESFATIN polypeptides has the nucleotide shown in SEQ ID NO 1,12-19,45-77
Sequence.
Preferably, the transformant of the NESFATIN polypeptides has SEQ ID NO 23-45,67-72,93-104,113-
Nucleotide sequence shown in 118.
Preferably, the NESFATIN polypeptides can be applicable to suppress the diagnosis of relevant disease with food rcstriction and increased weight
And treatment aspect, apply also for the research of the influencing mechanisms such as epilepsy, brain memory function.
Preferably, the screening technique with food rcstriction or body weight increase suppression therapy agent, comprises the following steps：
Step S1, under the catalytic action of prohormone convertase, NESFATIN polypeptides are decomposed, by the decomposition of gained
Product is injected in respectively in mouse peritoneal；
Mice after step S2, observation injection NESFATIN polypeptide breakdown products, and to the amino acid N dististyle in mice body
The expression inhibiting result of section, intermediate segment and C-terminal fragment is detected so as to obtain NESFATIN polypeptides there is food rcstriction to live
The critical sites of property and body weight increase inhibitory activity；
Step S3, by obtain with food rcstriction activity and body weight increase inhibitory activity NESFATIN polypeptides in pass
Key mapping point utilizes existing Medical Technology, prepares and has food rcstriction or body weight increase suppression therapy agent
Preferably, the screening technique of the brain tonic of the hypermnesis, comprises the following steps：
Step S1, under the catalytic action of prohormone convertase, NESFATIN polypeptides are decomposed, by the decomposition of gained
Product is injected in respectively in mouse brain nerve；
Mice after step S2, observation injection NESFATIN polypeptide breakdown products, and to the amino acid N dististyle of mice intracerebral
The expression inhibiting result of section, intermediate segment and C-terminal fragment is detected there is enhancing brain note so as to obtain NESFATIN polypeptides
Recall the critical sites of functional activity；
Critical sites in step S3, the NESFATIN polypeptides active with brain memory function is strengthened that will be obtained are utilized
Existing Medical Technology, prepares the brain tonic of hypermnesis.
A kind of NESFATIN polypeptides proposed by the present invention, with obvious food rcstriction and body weight increase inhibitory action, tool
There are memory function mechanism and enhancement mechanism and epilepsy interference mechanism, the present invention proposes the preparation method of NESFATIN polypeptides, using anti-
Quick-fried glass reactor, is added aminoacid in reactor by known sequence, and reactant is stirred using the mode of nitrogen bubble
Mixing is obtained, and preparation method is simple, and preparation condition is gentle, and low cost needed for preparing, the NESFATIN polypeptides of preparation can be used as and take the photograph
Food obstacle and weight regulation relevant disease, epilepsy and brain memory function strengthen the treatment of related fields, and the present invention is also carried
The screening technique of the brain tonic of screening technique and hypermnesis with food rcstriction or body weight increase suppression therapy agent is gone out, has grasped
Make simple, be worthy to be popularized.
Specific embodiment
The present invention is made with reference to specific embodiment further explain.
Embodiment
A kind of NESFATIN polypeptides proposed by the present invention, are a kind of new anorexia neuropeptides, from nucleohistone 2,
It includes 420 aminoacid, with the aminoacid sequence shown in SEQ ID NO 3-13,42-58,77-85,112-132, its system
Preparation Method is：Prepare implosion guard reactor, from the nitrogen introduced below of reactor, be passed through the nitrogen of reactor from reactor
Top is discharged, and aminoacid is added in reactor by known sequence, and reactant is stirred using the mode of nitrogen bubble, from
And NESFATIN polypeptides are obtained；
NESFATIN polypeptides are a kind of food intake regulation factors, are also a kind of weight regulation factors, the work with food rcstriction
Property, the activity for also suppressing with body weight increase；
NESFATIN polypeptides are widely present in hypothalamuses and brain stem, are also present in periphery digestive system；
NESFATIN polypeptides can decompose under the catalytic action of prohormone convertase, and catabolite is
NESFATIN-1 is located at the N-terminal of NUCB2, the peptide chain being made up of front 82 aminoacid；
The carrier of NESFATIN polypeptides has the nucleotide sequence shown in SEQ ID NO 1,12-19,45-77；
The transformant of NESFATIN polypeptides has the core shown in SEQ ID NO 23-45,67-72,93-104,113-118
Nucleotide sequence；
NESFATIN polypeptides can be applicable to suppress the diagnosis and treatment aspect of relevant disease with food rcstriction and increased weight,
Apply also for the research of the influencing mechanisms such as epilepsy, brain memory function；
Screening technique with food rcstriction or body weight increase suppression therapy agent, comprises the following steps：
Step S1, under the catalytic action of prohormone convertase, NESFATIN polypeptides are decomposed, by the decomposition of gained
Product is injected in respectively in mouse peritoneal；
Mice after step S2, observation injection NESFATIN polypeptide breakdown products, and to the amino acid N dististyle in mice body
The expression inhibiting result of section, intermediate segment and C-terminal fragment is detected so as to obtain NESFATIN polypeptides there is food rcstriction to live
The critical sites of property and body weight increase inhibitory activity；
Step S3, by obtain with food rcstriction activity and body weight increase inhibitory activity NESFATIN polypeptides in pass
Key mapping point utilizes existing Medical Technology, prepares and has food rcstriction or body weight increase suppression therapy agent.
The screening technique of the brain tonic of hypermnesis, comprises the following steps：
Step S1, under the catalytic action of prohormone convertase, NESFATIN polypeptides are decomposed, by the decomposition of gained
Product is injected in respectively in mouse brain nerve；
Mice after step S2, observation injection NESFATIN polypeptide breakdown products, and to the amino acid N dististyle of mice intracerebral
The expression inhibiting result of section, intermediate segment and C-terminal fragment is detected there is enhancing brain note so as to obtain NESFATIN polypeptides
Recall the critical sites of functional activity；
Critical sites in step S3, the NESFATIN polypeptides active with brain memory function is strengthened that will be obtained are utilized
Existing Medical Technology, prepares the brain tonic of hypermnesis.
A kind of NESFATIN polypeptides proposed by the present invention, with obvious food rcstriction and body weight increase inhibitory action, tool
There are memory function mechanism and enhancement mechanism and epilepsy interference mechanism, the present invention proposes the preparation method of NESFATIN polypeptides, using anti-
Quick-fried glass reactor, is added aminoacid in reactor by known sequence, and reactant is stirred using the mode of nitrogen bubble
Mixing is obtained, and preparation method is simple, and preparation condition is gentle, and low cost needed for preparing, the NESFATIN polypeptides of preparation can be used as and take the photograph
Food obstacle and weight regulation relevant disease, epilepsy and brain memory function strengthen the treatment of related fields, and the present invention is also carried
The screening technique of the brain tonic of screening technique and hypermnesis with food rcstriction or body weight increase suppression therapy agent is gone out, has grasped
Make simple, be worthy to be popularized.
The above, the only present invention preferably specific embodiment, but protection scope of the present invention is not limited thereto,
Any those familiar with the art the invention discloses technical scope in, technology according to the present invention scheme and its
Inventive concept equivalent or change in addition, all should be included within the scope of the present invention.
Claims (10)
1. a kind of NESFATIN polypeptides, it is characterised in that the NESFATIN polypeptides are a kind of new anorexia neuropeptides, source
In nucleohistone 2, the NESFATIN polypeptides are a kind of food intake regulation factors, are also a kind of weight regulation factors；
The preparation method of the NESFATIN polypeptides is：Prepare implosion guard reactor, from the nitrogen introduced below of reactor, lead to
The nitrogen for entering reactor is discharged from the top of reactor, aminoacid is added in reactor, using nitrogen bubble by known sequence
Mode reactant is stirred, so as to NESFATIN polypeptides are obtained.
2. a kind of NESFATIN polypeptides according to claim 1, it is characterised in that the NESFATIN polypeptides have ingests
The activity of suppression, the activity for also suppressing with body weight increase.
3. a kind of NESFATIN polypeptides according to claim 1, it is characterised in that the decomposition of the NESFATIN polypeptides is produced
Thing NESFATIN-1 is located at the N-terminal of NUCB2, the peptide chain being made up of front 82 aminoacid.
4. a kind of NESFATIN polypeptides according to claim 1, it is characterised in that the NESFATIN polypeptides can be in hormone
Decompose under the catalytic action of former invertase.
5. a kind of NESFATIN polypeptides according to claim 1, it is characterised in that characterized in that, the NESFATIN
Polypeptide includes 420 aminoacid, with the aminoacid sequence shown in SEQ ID NO 3-13,42-58,77-85,112-132.
6. a kind of NESFATIN polypeptides according to claim 1, it is characterised in that the carrier tool of the NESFATIN polypeptides
There is the nucleotide sequence shown in SEQ ID NO 1,12-19,45-77.
7. a kind of NESFATIN polypeptides according to claim 1, it is characterised in that the transformant of the NESFATIN polypeptides
With the nucleotide sequence shown in SEQ ID NO 23-45,67-72,93-104,113-118.
8. a kind of NESFATIN polypeptides according to claim 1, it is characterised in that the NESFATIN polypeptides can be applicable to
Diagnosis and treatment aspect with food rcstriction and increased weight suppress relevant disease, applies also for epilepsy, brain memory
The research of the influencing mechanisms such as function.
9. the application of a kind of NESFATIN polypeptides according to claim 8, it is characterised in that it is described with food rcstriction or
The screening technique of body weight increase suppression therapy agent, comprises the following steps：
Step S1, under the catalytic action of prohormone convertase, NESFATIN polypeptides are decomposed, by the catabolite of gained
It is injected in respectively in mouse peritoneal；
Step S2, observation injection NESFATIN polypeptide breakdown products after mice, and to the amino acid N end fragment in mice body,
The expression inhibiting result of intermediate segment and C-terminal fragment is detected there is food rcstriction activity so as to obtain NESFATIN polypeptides
With the critical sites of body weight increase inhibitory activity；
Step S3, by obtain with food rcstriction activity and body weight increase inhibitory activity NESFATIN polypeptides in crucial position
Point utilizes existing Medical Technology, prepares and has food rcstriction or body weight increase suppression therapy agent.
10. a kind of application of the NESFATIN polypeptides described in claim 8, it is characterised in that the brain tonic of the hypermnesis
Screening technique, comprise the following steps：
Step S1, under the catalytic action of prohormone convertase, NESFATIN polypeptides are decomposed, by the catabolite of gained
It is injected in respectively in mouse brain nerve；
Mice after step S2, observation injection NESFATIN polypeptide breakdown products, and the amino acid N end fragment to mice intracerebral,
The expression inhibiting result of intermediate segment and C-terminal fragment is detected there is enhancing brain memory so as to obtain NESFATIN polypeptides
The critical sites of functional activity；
Critical sites in step S3, the NESFATIN polypeptides active with brain memory function is strengthened that will be obtained are using existing
Medical Technology, prepare the brain tonic of hypermnesis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611078821.2A CN106589101A (en) | 2016-11-30 | 2016-11-30 | NESFATIN polypeptide and its related substance and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611078821.2A CN106589101A (en) | 2016-11-30 | 2016-11-30 | NESFATIN polypeptide and its related substance and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106589101A true CN106589101A (en) | 2017-04-26 |
Family
ID=58594325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611078821.2A Pending CN106589101A (en) | 2016-11-30 | 2016-11-30 | NESFATIN polypeptide and its related substance and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106589101A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008253265A (en) * | 2007-04-06 | 2008-10-23 | Teijin Pharma Ltd | Method for screening nesfatin-1 action controlling substance or substance with nesfatin-1-like action using receptor protein selected from group consisting of gpr3, gpr6 and gpr12 |
| CN101300346A (en) * | 2005-06-24 | 2008-11-05 | 帝人制药株式会社 | Novel biological substance nesfatin and its related substances and uses thereof |
| US20100234274A1 (en) * | 2009-03-12 | 2010-09-16 | Jian-Ning Liu | Use of Nestafin-1 in the Treatment for Diabetes |
| CN101914150A (en) * | 2009-03-12 | 2010-12-15 | 刘建宁 | Polypeptide and use thereof in medicament preparation |
-
2016
- 2016-11-30 CN CN201611078821.2A patent/CN106589101A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101300346A (en) * | 2005-06-24 | 2008-11-05 | 帝人制药株式会社 | Novel biological substance nesfatin and its related substances and uses thereof |
| JP2008253265A (en) * | 2007-04-06 | 2008-10-23 | Teijin Pharma Ltd | Method for screening nesfatin-1 action controlling substance or substance with nesfatin-1-like action using receptor protein selected from group consisting of gpr3, gpr6 and gpr12 |
| US20100234274A1 (en) * | 2009-03-12 | 2010-09-16 | Jian-Ning Liu | Use of Nestafin-1 in the Treatment for Diabetes |
| CN101914150A (en) * | 2009-03-12 | 2010-12-15 | 刘建宁 | Polypeptide and use thereof in medicament preparation |
Non-Patent Citations (1)
| Title |
|---|
| 刘诤 等: "神经肽Ghrelin和Nesfatin-1的研究进展", 《宁夏医科大学学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mondal et al. | Coordination of motilin and ghrelin regulates the migrating motor complex of gastrointestinal motility in Suncus murinus | |
| RU2275207C2 (en) | Method for decreasing of nutrient availability and method for appetite suppression | |
| KR101361603B1 (en) | Composition for amelioration of body lipid | |
| Strand | Neuropeptides: general characteristics and neuropharmaceutical potential in treating CNS disorders | |
| DE19531931A1 (en) | Body weight modulators, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof | |
| US20100222284A1 (en) | Composition for inhibiting the onset of arteriosclerosis and inhibition method | |
| Kuroda et al. | Ghrelin is an essential factor for motilin-induced gastric contraction in Suncus murinus | |
| JP2001031586A (en) | Composition for prophylaxis or therapy of both arteriosclerosis and disease caused thereby | |
| JP5158779B2 (en) | Antihypertensive agent comprising D-allose as an active ingredient | |
| CN106589101A (en) | NESFATIN polypeptide and its related substance and use | |
| Sodhi et al. | Harnessing potential of A2 milk in India: An overview | |
| Dury | Changes in circulating eosinophiles and adrenal ascorbic acid concentration after agents altering blood sugar levels and after surgical conditions | |
| JP2003104879A (en) | Healthy food and preparation having diet effect | |
| US20180289727A1 (en) | Composition for preventing or treating vascular leak syndrome | |
| US10806800B2 (en) | Pharmaceutical composition containing hyaluronic acid nanoparticles for preventing or treating inflammatory disease and metabolic disease | |
| JP7030524B2 (en) | Glucoraphanin for use in the treatment and / or prevention of diabetes mellitus | |
| AU2009310912A1 (en) | Peptide having anti-diabetic activity and use thereof | |
| EP1325743A1 (en) | Compositions for improving lipid metabolism | |
| KR20220147536A (en) | Food Composition and Pharmaceutical Composition for preventing or improving sarcopenia comprising low-molecular collagen as an active ingredient | |
| WO2010058517A1 (en) | NERVE CELL STIMULATOR COMPRISING IgG AND/OR Fc FRAGMENT OF IgG | |
| Dao et al. | Human growth hormone | |
| JPH06178654A (en) | Feed for chicken | |
| EP1862197A2 (en) | Use of a protein concentrate | |
| Urunbayeva et al. | THE ROLE OF VITAMIN D DURING PRIMARY EXOGENOUS CONSTITUTIONAL OBESITY IN WOMEN | |
| EP1229927B1 (en) | Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170426 |